Dr. Wakelee on Adjuvant Therapy Predictive Markers

Dr. Heather Wakelee from Stanford Clinical Cancer Center Discusses Adjuvant Therapy Predictive Markers

Heather Wakelee, MD, assistant professor, Department of Medicine, Division of Oncology, Stanford University, Stanford Clinical Cancer Center, discusses markers currently under investigation that could be used to predict adjuvant chemotherapy benefit in lung cancer patients.

DNA repair enzymes receive the most attention as potential benefit predictors of postoperative therapy. The theory in place is that if these markers are high the tumor will be more likely to build up a resistance to chemotherapy, and contrive less of a benefit.

The most common marker currently being investigated is the ERCC1 DNA repair protein that is encoded by the ERCC1 gene. This marker is still under investigation, but could lead to a clearer understanding of which patients would respond the most to adjuvant cisplatin.

A retrospective examination of a prognostic trial looking at untreated resected non-small cell lung cancer patients showed that ERCC1-positive patients had an increased rate of survival compared to those that are ERCC1-negative. This information suggests that ERCC1-negative patients will benefit the most from cisplatin chemotherapy.

Related Videos
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Alastair Thompson, BSc, MBChB, MD, FRCS
C. Ola Landgren, MD, PhD
Sara M. Tolaney, MD, MPH
Adam M. Brufsky, MD, PhD, FACP
Justin M. Watts, MD
Sara M. Tolaney, MD, MPH
Leah Backhus, MD, MPH, FACS, professor, University Medical Line, Cardiothoracic Surgery, co-director, Thoracic Surgery Clinical Research Program, associate program director, Thoracic Track, CT Surgery Residency Training Program, Thelma and Henry Doelger Professor of Cardiovascular Surgery, Stanford Medicine; chief, Thoracic Surgery, VA Palo Alto
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine